The administration of TA in cardiac surgery has not been associated with severe adverse events. However, current studies and case series reports mention an increased incidence of seizures after administration of high TA doses (60-260 mg kg 21 body weight). 3 -7 In addition, one recent small retrospective analysis associated high TA doses (100 mg kg 21 body weight) with an increased mortality risk in patients undergoing open-heart procedures when compared with aprotinin. 3 At our institution, we use a protocol with a more moderate ( 25 mg kg 21 body weight) dose, which approximates the suggested dose for achieving an effective inhibition of fibrinolysis during cardiac surgery. 8 -10 We herein report our single-centre experience with this moderate dose of TA on convulsive seizures (CS) and other clinical outcome parameters in a large cohort of cardiac surgery patients.
between January 2008 and December 2009. Out of 6201 consecutive patients who underwent cardiopulmonary bypass (CPB) surgery at the Heart and Diabetes Centre North Rhine-Westphalia, Germany, 4883 patients were finally included in the data analysis (Fig. 1) . The database consisted of perioperative data which were prospectively collected. All cardiac surgical patients were asked to give their general written permission before the operation in the scientific analysis and possible publication of anonymized data. The local Ethics Committee had approved this approach. The study was performed according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement for cohort studies (www .strobe-statement.org).
Data collection
All clinical data were collected using the digital patient data management system PDMS (COPRA, Sasbachwalden, Germany). In total, 21 parameters were retrieved for each patient. Among them, 19 patients and surgery characteristics [age, sex, weight, left ventricular ejection fraction, concomitant diagnoses such as stroke, diabetes mellitus, cardiovascular disease, pulmonary disease, peripheral arterial occlusive disease, and hypertension, estimated glomerular filtration rate (eGFR), previous thoracic surgery, aspirin use, open-heart surgery, aortic cross clamp time, duration of CPB, transfusion requirement, and catecholamine requirement], two event categories (CS and in-hospital mortality), and two other outcome parameters [duration of mechanical ventilatory support and intensive care unit (ICU) stay] were assessed.
Primary endpoint
The primary endpoint was the rate of CS observed on the ICU. A CS was considered to have occurred in the case of sudden clonic movement of the patient. The suspicion of the occurrence of a CS was immediately reported from the specially trained nursing staff to the responsible physician who confirmed the diagnosis. Only in the case of re-occurrence or the suspicion of persisting neurological damage, a specialized neurologist was involved and further diagnostics (CT scan and electroencephalogram) were performed.
Secondary endpoints
Secondary endpoints were the duration of mechanical ventilatory support, duration of ICU stay, and in-hospital mortality.
Biochemical analyses
Preoperative creatinine was measured using the Architect autoanalyzer (Abbott, Wiesbaden, Germany). Then, GFR was estimated using the creatinine-based modification of diet in renal disease formula.
Eligible patients n=6201
Excluded patients
Off-pump surgery, n=518
Incomplete data sets Missing data on LVEF, hypertonus,
DM, n=800
Patients considered for data analysis n=5683
Patients included in data analysis n=4883 
TA administration
The recommended dose from the German package insert of TA is a bolus of 1000 mg for the patient and 500 mg for the CPB circuit followed by a continuous infusion of 400 mg h 21 during surgery. The dosing regimen used at our clinic is slightly lower with the same boluses but a continuous infusion rate of 200 mg h 21 limited to the time during CPB. It is suggested that this dose achieves an effective inhibition of fibrinolysis during CPB. 8 -10 A dose adjustment in patients with impaired renal function was not performed due to the use of intraoperative haemofiltration in patients with a GFR of ,40 ml min 21 . There was no strict institutional protocol regarding TA administration. The use of TA was at the discretion of the surgeon and the anaesthesiologist. Typical indications for TA were active anti-platelet therapy, re-operations, and complex procedures with an expected CPB time exceeding 90 min. TA was given after systemic heparinization.
Statistics
We report categorical variables as observational percentages. Continuous variables are presented as mean (SD). We tested normal distribution of the data using the KolmogorovSmirnov test. The patient characteristic and clinical parameters of patients who received or did not receive TA were compared with Student's t-test, Mann -Whitney test, or Fisher's exact test as appropriate. We tested the association between TA use/non-use and clinical outcomes using univariable and multivariable binary logistic regression analysis. Results are presented as odds ratio (OR) with a 95% confidence interval (CI). The group not receiving TA was used as the reference group. Since the number of variables that can be included for multivariable testing equals 10% or the square root of the number of events, 11 in the present study, the multivariable regression analysis could only contain up to 2-4 covariates. We therefore performed a propensity score (PS) adjustment, which prevented us from over-parameterizing the model. 12 The risk score derivation model was constructed with multivariable logistic regression, with the TA group as the binominal-dependent variable and the variables listed in Table 1 as predictor variables. The model's reliability and predictive ability were 
Results

Baseline characteristics
Basic patient characteristics are presented in Table 1 . The two study groups were comparable with respect to gender distribution, body weight, and prevalence of diabetes mellitus, hypertension, and preoperative neurological complications. However, in comparison with the reference group, patients in the TA group were older and slightly heavier, had a slightly higher prevalence of pulmonary disease and peripheral arterial occlusive disease, were more often undergoing re-do procedures, were less likely to have a preoperative ventricular ejection fraction of .55%, suffered more frequently from coronary heart disease, and were more often using aspirin, but had slightly higher eGFR values. CABG surgery was performed less often and combined CABG and valve surgery more often in the TA group than in the reference group. In addition, the duration of CPB and aortic cross clamp time were significantly higher in the TA group than in the control group. Further, patients in the TA group required more blood transfusions and pharmacological inotropic support with catecholamines than patients of the reference group. In the TA group, the mean (SD) administered TA dose was 24.0 (5.5) mg kg 21 body weight. The total TA dose was 1833 (144) mg.
Primary endpoint
In total, 73 CS occurred. The incidence of CS was 2.5% in the TA group and was approximately twice as high compared with the reference group ( In the 1318 patients who were excluded from data analysis, 295 patients received TA. In the entire group of excluded patients, 12 CS occurred (incidence: 0.91%). When the excluded patients were included in the logistic regression analysis, the OR of CS remained significantly higher in the TA group than in the reference group (OR¼2.25, 95% CI: 1.45 -3.51; P,0.001).
Secondary endpoints
Results of the secondary endpoints are presented in Table 2 according to the study group. Log-duration of mechanical ventilatory support and log-ICU stay were significantly longer in the TA group than in the reference group, even after adjustments were made for the potential preoperative and perioperative confounders listed in Table 1 (P¼0.004 and 0.008). We also investigated the effect of CS on clinical outcome. In both the TA and the reference groups, the duration of mechanical ventilatory support, ICU stay, and in-hospital mortality was significantly higher in patients experiencing CS compared with CS-free patients (Table 3) .
Because the type of cardiac surgery also may be in the causal pathway between TA administration and in-hospital mortality, we used statistical models to test potential associations. Again, in the subgroup of patients with CABG-only surgery (n¼2104), the OR of in-hospital mortality for the TA group was not statistically significant: OR¼1.13 (95% CI: 0.42 -3.02; P¼0.809). This is in contrast again to the results of the subgroup of patients with open-heart surgery (n¼2779), where the OR of in-hospital mortality for the TA group was 2.20 (95% CI: 1.32-3.69; P¼0.003). In the TA group, the total TA dose was slightly but significantly higher in the subgroup of patients with open-heart surgery compared with the subgroup of CABG-only surgery [1872 (149) vs 1770 (109) mg; P,0.001]. Table 4 outlines the study endpoints according to the surgical procedure in the TA and reference groups.
In Table 5 , the TA dose and some perioperative data are presented according to the occurrence or absence of seizures in patients with and without open-heart surgery.
Discussion
The present large retrospective data analysis from a single centre demonstrates that even moderate TA doses of on average 24 mg kg 21 are associated with an increased risk to experience CS, which after PS adjustment was attenuated, but still 70% higher compared with the reference group. However, this risk was less pronounced in patients undergoing CABG-only surgery compared with patients undergoing open-heart surgery. In addition, TA use was an independent Reference group, open heart (n52143)
TA group, open heart (n5636)
P-value
Primary endpoint
Convulsive seizures (%) 1. In-hospital mortality (%) 1.7 5.7 ,0.001 predictor of in-hospital mortality, especially in patients with open-heart surgery procedures. The incidence of CS after cardiac surgery is consistently reported to be within the range of 0.9 -1.2%. 13 14 Several recent investigations have described a dramatically increased CS rate in patients on TA administration, reaching 2.7 -7.6%. 3 -7 In our investigation, the CS rate in the TA group was 2.5% and thus at the lower end of the aforementioned range. The fact that TA promotes CS has been known for 20 yr. An increased CS rate was first observed in a neurosurgical animal model where fibrin glue that contained TA was administered topically. 15 The underlying biochemical mechanism appears to be a g-aminobutyric acid A receptor antagonist effect. 16 Compared with the patients of our data analysis, much higher TA doses have been used in the aforementioned earlier studies, that is, 70, 100, and 60-260 mg kg 21 , respectively. 3 -7 Although in our investigation, kidney function was related to CS risk, the fact that the total TA dose and body weight were not related to CS risk indicates that there may be no strong relationship between TA bioavailability and CS risk. However, note that we do not adjust the TA dose to renal function because we perform intraoperative haemofiltration in case eGFR values decrease below 40 ml min 21 . The higher transfusion requirement in the TA group compared with the reference group can reliably be explained by their higher risk profile including increased preoperative medication with anti-platelet agents and more complex surgery. It was another important finding of our study that the CS risk was only enhanced in open-heart surgery but not in CABG-only surgery. Our results confirm earlier findings by Murkin and colleagues. 5 The underlying causes for the aforementioned differences in the incidence of CS are unknown at present. It is well known that changes in blood -brain barrier permeability caused by ischaemia, certain proteins, or inflammatory substances play a pivotal role in a large number of diseases of the central nervous system (CNS). 17 18 Those changes may lead to increased permeability for TA and toxic cerebral TA concentrations. Diffuse cerebral air-embolism in openheart surgery, an increased systemic inflammatory response due to prolonged CPB, and severe electrolyte imbalances in patients with renal impairment might cause such disturbances of blood -brain barrier permeability. Another significant and unexpected observation of this investigation was that in-hospital mortality was approximately twice as high in the total TA group compared with the reference group, even after PS adjustment was performed. Once more, it was an important finding that this association was restricted to patients with open-heart surgery. These results are comparable with an earlier investigation by Sander and colleagues. 3 In that study, compared with aprotinin administration, TA administration was associated with a doubling of the mortality risk in the subgroup of patients undergoing open-heart surgery. However, it is noteworthy that mortality risk remained significantly enhanced in our investigation, even when the postoperative presence or absence of CS was added to the PS-adjusted model. This suggests a TA effect on mortality which is independent of the presence of CS. Nevertheless, it is also noteworthy that our results support earlier findings of an impaired clinical outcome in patients experiencing CS. 13 In both the TA and reference groups of our study, in-hospital mortality was 4.5-5.0 times higher in the subgroups of patients experiencing CS compared with patients without CS. The in-hospital mortality of 19.1% in patients receiving TA and experiencing CS is unacceptably high and cannot be explained by a transient antagonistic effect on a receptor of the CNS. The high mortality rate of up to 19 .1% in open-heart surgery does not justify the use of TA in this patient group.
Our investigation has some limitations. First, the observational nature of the study design precludes us from concluding that there is a causal relation between TA administration and clinical outcome. Although we used a PS-adjusted model which considered various pre-and intraoperative parameters, residual confounding may still exist. Secondly, the CS were only evaluated clinically by the specially trained nursing staff and the physician on duty on the ICU. This has to be attributed to the fact that in our specialized 3 -5 In addition, as this procedure applied for all patients, any potential errors should be equally distributed between the two study groups observed. Thirdly, we did not review the charts of our patients with respect to the event of stroke. The association of CS with stroke in a cardiac surgery ICU is unknown at present. In a large prospective investigation assessing the incidence of CS after stroke, only 8.9% of the patients exhibited a single event or repetitive CS after stroke. 19 In another large retrospective analysis of 6044 stroke patients, the overall incidence was 3.1% with 8.4% in patients with haemorrhagic stroke and 2.4% in patients with ischaemic stroke. 20 Due to this rare association, even the evidence of a stroke in a patient receiving TA would not have ruled out that TA provoked the CS. Fourthly, we assessed CS only in the ICU. A CABG-only patient would be in an ICU setting for less time and the chance of being witnessed is lower than in a higher risk patient, for example, a patient with openheart surgery. However, since we compared the TA group with a reference group not receiving TA, the aforementioned aspect should not influence our results systematically. It is also noteworthy that the occurrence of TA-induced CS is rather unlikely after discharge from the ICU.
In conclusion, this large set of data indicates that even moderate dosages of TA are associated with a nearly doubled rate of CS and detrimental clinical outcome of cardiac surgery patients. Particularly, patients undergoing open-heart surgery procedures are at an increased risk. The findings can hardly be explained by a temporary antagonistic pharmacological TA effect on a special receptor in the CNS. Even moderate dosages of TA should be used with caution in patients undergoing open-heart procedures. The new insights into clinically significant side-effects of TA and the potentially increased risk for in-hospital mortality show that large controlled prospective clinical trials are needed to further evaluate the safety profile of TA. 
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